Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

News Conference News TCT 2024

Protecting Coronary Access After TAVI: Valve Choice Clues From CAVEAT

Michael O'Riordan

October 27, 2024

News Conference News TCT 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

Shelley Wood

September 07, 2022

News Conference News TCT 2019

Leave It Be: PCI for Stable CAD Before or With TAVR Does Not Lower Mortality Risk

Michael O'Riordan

September 29, 2019

News Opinion Editor's Corner TCT 2018

TCT 2018, Day Four: Bioresorbable Scaffolds, Renal Denervation, Head-to-Head TAVR, INOCA, and . . . That’s a Wrap!

Shelley Wood

September 25, 2018

News Conference News TCT 2018

PCI vs CABG at 10 Years: MAIN-COMPARE and SYNTAXES Shine Light on Long-term Outcomes

Michael O'Riordan

September 25, 2018

News Industry News TCT 2016

Imaging Study Shows Rate of Strut Coverage and Low Rates of Neouatherosclerosis with Thin Strut Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting Stents

November 02, 2016

News Industry News TCT 2016

Hybrid Sirolimus-Eluting Stents with Biodegradable Polymer Did Not Improve Angiographic Outcomes Compared to Everolimus-Eluting Stents with Durable Polymer in Treatment of Chronic Total Occlusions

November 02, 2016

News Industry News TCT 2016

Study Finds No Long-Term Clinical Benefit to Routine Follow-Up Coronary Angiography After PCI

November 01, 2016

News Conference News

ROTAXUS: Rotablation Does Not Improve Stenting Results in Calcified Lesions

Yael L. Maxwell

November 30, 2011

News Conference News

COBRA: Postdilation with Cryoplasty Reduces Restenosis in Diabetic SFA Lesions

Jason Kahn

November 30, 2011

News Conference News

TWENTE: Zotarolimus DES Noninferior to Everolimus DES at 1 Year

L.A. McKeown

November 28, 2011

News Conference News

PEPCAD-DES: Drug-Coated Balloon Better Than Uncoated Balloon for DES Restenosis

November 27, 2011

News Conference News

RIBS III: Alternative DES Best Bet for DES In-Stent Restenosis

November 22, 2011

News Conference News

Stent Thrombosis Linked to Uncovered, Malapposed Stent Struts

November 21, 2011

News Conference News

Paclitaxel-Eluting Bioabsorbable Stent Shows Advantage over Bare-Metal Version

November 20, 2011

Advertisement

What’s Going to Be Hot at TCT 2025

Protecting Coronary Access After TAVI: Valve Choice Clues From CAVEAT

New Faces, New Formats, New Tech: What to Expect From TCT 2022

Leave It Be: PCI for Stable CAD Before or With TAVR Does Not Lower Mortality Risk

TCT 2018, Day Four: Bioresorbable Scaffolds, Renal Denervation, Head-to-Head TAVR, INOCA, and . . . That’s a Wrap!

PCI vs CABG at 10 Years: MAIN-COMPARE and SYNTAXES Shine Light on Long-term Outcomes

Imaging Study Shows Rate of Strut Coverage and Low Rates of Neouatherosclerosis with Thin Strut Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting Stents

Hybrid Sirolimus-Eluting Stents with Biodegradable Polymer Did Not Improve Angiographic Outcomes Compared to Everolimus-Eluting Stents with Durable Polymer in Treatment of Chronic Total Occlusions

Study Finds No Long-Term Clinical Benefit to Routine Follow-Up Coronary Angiography After PCI

ROTAXUS: Rotablation Does Not Improve Stenting Results in Calcified Lesions

COBRA: Postdilation with Cryoplasty Reduces Restenosis in Diabetic SFA Lesions

TWENTE: Zotarolimus DES Noninferior to Everolimus DES at 1 Year

PEPCAD-DES: Drug-Coated Balloon Better Than Uncoated Balloon for DES Restenosis

RIBS III: Alternative DES Best Bet for DES In-Stent Restenosis

Stent Thrombosis Linked to Uncovered, Malapposed Stent Struts

Paclitaxel-Eluting Bioabsorbable Stent Shows Advantage over Bare-Metal Version

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content